GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » EV-to-FCF

Formycon AG (XTER:FYB) EV-to-FCF : -25.28 (As of May. 19, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Formycon AG's Enterprise Value is €784.65 Mil. Formycon AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-31.04 Mil. Therefore, Formycon AG's EV-to-FCF for today is -25.28.

The historical rank and industry rank for Formycon AG's EV-to-FCF or its related term are showing as below:

XTER:FYB' s EV-to-FCF Range Over the Past 10 Years
Min: -1324.89   Med: -53.81   Max: 26.41
Current: -25.28

During the past 13 years, the highest EV-to-FCF of Formycon AG was 26.41. The lowest was -1324.89. And the median was -53.81.

XTER:FYB's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs XTER:FYB: -25.28

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-19), Formycon AG's stock price is €44.30. Formycon AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €4.720. Therefore, Formycon AG's PE Ratio for today is 9.39.


Formycon AG EV-to-FCF Historical Data

The historical data trend for Formycon AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG EV-to-FCF Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -118.94 -93.98 -44.11 -29.10 -29.24

Formycon AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.11 - -29.10 - -29.24

Competitive Comparison of Formycon AG's EV-to-FCF

For the Biotechnology subindustry, Formycon AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Formycon AG's EV-to-FCF falls into.



Formycon AG EV-to-FCF Calculation

Formycon AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=784.646/-31.044
=-25.28

Formycon AG's current Enterprise Value is €784.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-31.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG  (XTER:FYB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Formycon AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=44.30/4.720
=9.39

Formycon AG's share price for today is €44.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €4.720.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Formycon AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Formycon AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG (XTER:FYB) Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines